FULC News and Press, Fulcrum Therapeutics Inc. From 02/26/24

2024-02-26 05:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. ® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today a...

CAMBRIDGE, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announ...

2024-01-25 09:18:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives of patients with genetically defined rare diseases, today announced that management will parti...

Fulcrum Therapeutics, Inc. (NASDAQ: FULC) is one of today's top gainers. The company's shares have moved 5.66% on the day to $3.36. Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically define...

2023-11-07 10:12:07 ET Fulcrum Therapeutics, Inc. (FULC) Q3 2023 Earnings Conference Call Nov 08, 2023, 08:00 AM ET Company Participants Chris Calabrese - LifeSci Advisors, LLC Alex Sapir - President and Chief Executive Officer Alan Musso - Chief Financial Office...

2023-11-07 07:16:01 ET More on Fulcrum Therapeutics An Updated View On Fulcrum Therapeutics Fulcrum's Balance: Between Promise And Uncertainty Fulcrum upgraded to buy at Stifel on ending of clinical hold Biggest stock movers today: Macy's, DICK'S Sporting Goo...

― Completed enrollment in the Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD); expect to report topline data in the fourth quarter of 2024 ― ― U.S. Food and Drug Administration (FDA) lifted clinical hold for pociredir (formerly FTX-6...

Weyco Group Inc. (WEYS) is expected to report for Q1 2024 Gladstone Land Corporation (LAND) is expected to report $0.16 for Q3 2023 PlayAGS Inc. (AGS) is expected to report $0.01 for Q3 2023 Ardmore Shipping Corporation (ASC) is expected to report $0.43 for Q3 2023 Sage Therapeuti...